C4 Therapeutics logo

C4 Therapeutics Share Price Today

(NASDAQ: CCCC)

C4 Therapeutics share price is $3.55 & ₹310.37 as on 8 Feb 2025, 2.30 'hrs' IST

$3.55

-0.03

(-0.84%)

Market is closed - opens 8 PM, 10 Feb 2025

View live C4 Therapeutics share price in Dollar and Rupees. Guide to invest in C4 Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in C4 Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

C4 Therapeutics share price movements

  • Today's Low: $3.50
    Today's High: $3.68

    Day's Volatility :5.03%

  • 52 Weeks Low: $3.25
    52 Weeks High: $11.88

    52 Weeks Volatility :72.64%

C4 Therapeutics (CCCC) Returns

PeriodC4 Therapeutics, IncSector (Health Care)Index (Russel 2000)
3 Months
-39.63%
-2.5%
0.0%
6 Months
-37.94%
-2.4%
0.0%
1 Year
-47.49%
1.7%
0.0%
3 Years
-84.98%
10.9%
-13.8%

C4 Therapeutics (CCCC) Key Statistics

in dollars & INR

Previous Close
$3.58
Open
$3.59
Today's High
$3.68
Today's Low
$3.495
Market Capitalization
$250.6M
Today's Volume
$510.9K
52 Week High
$11.88
52 Week Low
$3.25
Revenue TTM
$33.7M
EBITDA
$-115.1M
Earnings Per Share (EPS)
$-1.71
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-46.0%

How to invest in C4 Therapeutics Stock (CCCC) from India?

It is very easy for Indian residents to invest directly in C4 Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the C4 Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for C4 Therapeutics or CCCC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of C4 Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of C4 Therapeutics shares which would translate to 0.246 fractional shares of C4 Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like C4 Therapeutics, in just a few clicks!

Returns in C4 Therapeutics (CCCC) for Indian investors in Rupees

The C4 Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

C4 Therapeutics investment value today

Current value as on today

₹57,851

Returns

₹42,149

(-42.15%)

Returns from C4 Therapeutics Stock

₹47,485 (-47.49%)

Dollar Returns

₹5,336 (+5.34%)

Indian investors sentiment towards C4 Therapeutics (CCCC)

-32%

Period: Jan 10, 2025 to Feb 9, 2025. Change in 30 Days versus previous period

Search interest for C4 Therapeutics Stock from India on INDmoney has decreased by -32% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in C4 Therapeutics

  • Soleus Capital Management, L.P.

    9.36%

  • Wasatch Advisors LP

    8.04%

  • BlackRock Inc

    6.93%

  • RA Capital Management, LLC

    6.91%

  • Orbimed Advisors, LLC

    6.20%

  • COMMODORE CAPITAL LP

    4.83%

Analyst Recommendation on C4 Therapeutics

Buy

    73%Buy

    26%Hold

    0%Sell

Based on 15 Wall street analysts offering stock ratings for C4 Therapeutics(by analysts ranked 0 to 5 stars)

Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
13
Hold
4
4
4
Sell
0
0
0

Analyst Forecast on C4 Therapeutics Stock (CCCC)

What analysts predicted

Upside of 361.27%

Target:

$16.38

Current:

$3.55

Insights on C4 Therapeutics Stock (Ticker Symbol: CCCC)

  • Price Movement

    In the last 3 months, CCCC stock has moved down by -41.4%
  • Increasing Revenue

    Revenue is up for the last 3 quarters, 3.03M → 15.36M (in $), with an average increase of 48.3% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -17.71M → -24.66M (in $), with an average decrease of 39.2% per quarter
  • CCCC vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.4% return, outperforming this stock by 104.7%
  • CCCC vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 83.1% return, outperforming this stock by 168.2%
  • Price to Sales

    ForCCCC every $1 of sales, investors are willing to pay $6.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.7 for every $1 of sales.

CCCC C4 Therapeutics Financials in INR & Dollars

FY18Y/Y Change
Revenue
$19.4M
-
Net Income
$-15.7M
-
Net Profit Margin
-81.14%
-
FY19Y/Y Change
Revenue
$21.4M
↑ 10.42%
Net Income
$-34.1M
↑ 117.04%
Net Profit Margin
-159.48%
↓ 78.34%
FY20Y/Y Change
Revenue
$33.2M
↑ 55.25%
Net Income
$-66.3M
↑ 94.54%
Net Profit Margin
-199.83%
↓ 40.35%
FY21Y/Y Change
Revenue
$45.8M
↑ 37.93%
Net Income
$-86.0M
↑ 29.7%
Net Profit Margin
-187.92%
↑ 11.91%
FY22Y/Y Change
Revenue
$31.1M
↓ 32.08%
Net Income
$-126.5M
↑ 47.03%
Net Profit Margin
-406.8%
↓ 218.88%
FY23Y/Y Change
Revenue
$20.8M
↓ 33.25%
Net Income
$-132.5M
↑ 4.74%
Net Profit Margin
-638.34%
↓ 231.54%
Q2 FY23Q/Q Change
Revenue
$2.7M
↓ 29.13%
Net Income
$-35.9M
↑ 5.85%
Net Profit Margin
-1.3K%
↓ 445.57%
Q3 FY23Q/Q Change
Revenue
$11.1M
↑ 315.62%
Net Income
$-27.0M
↓ 24.73%
Net Profit Margin
-244.19%
↑ 1104.23%
Q4 FY23Q/Q Change
Revenue
$3.3M
↓ 70.55%
Net Income
$-34.8M
↑ 28.54%
Net Profit Margin
-1.1K%
↓ 821.56%
Q1 FY24Q/Q Change
Revenue
$3.0M
↓ 6.81%
Net Income
$-28.4M
↓ 18.4%
Net Profit Margin
-933.23%
↑ 132.52%
Q2 FY24Q/Q Change
Revenue
$12.0M
↑ 295.06%
Net Income
$-17.7M
↓ 37.53%
Net Profit Margin
-147.56%
↑ 785.67%
Q3 FY24Q/Q Change
Revenue
$15.4M
↑ 27.95%
Net Income
$-24.7M
↑ 39.23%
Net Profit Margin
-160.57%
↓ 13.01%
FY18Y/Y Change
Profit
$19.4M
-
FY19Y/Y Change
Profit
$-26.3M
↓ 235.73%
FY20Y/Y Change
Profit
$-44.3M
↑ 68.45%
FY21Y/Y Change
Profit
$42.9M
↓ 196.85%
FY22Y/Y Change
Profit
$23.5M
↓ 45.14%
FY23Y/Y Change
Profit
$-97.0M
↓ 512.13%
Q2 FY23Q/Q Change
Profit
$675.0K
↓ 60.22%
Q3 FY23Q/Q Change
Profit
$9.1M
↑ 1244.74%
Q4 FY23Q/Q Change
Profit
$1.6M
↓ 82.7%
Q1 FY24Q/Q Change
Profit
$1.0M
↓ 35.54%
Q2 FY24Q/Q Change
Profit
$10.0M
↑ 884.29%
Q3 FY24Q/Q Change
Profit
$13.3M
↑ 33.58%
FY18Y/Y Change
Operating Cash Flow
$-17.0M
-
Investing Cash Flow
$36.9M
-
Financing Cash Flow
$2.0M
-
FY19Y/Y Change
Operating Cash Flow
$55.6M
↓ 427.51%
Investing Cash Flow
$-1.6M
↓ 104.39%
Financing Cash Flow
$244.0K
↓ 87.56%
FY20Y/Y Change
Operating Cash Flow
$-67.2M
↓ 220.92%
Investing Cash Flow
$-190.5M
↑ 11659.57%
Financing Cash Flow
$348.9M
↑ 142904.92%
FY21Y/Y Change
Operating Cash Flow
$-87.0M
↑ 29.32%
Investing Cash Flow
$-189.3M
↓ 0.61%
Financing Cash Flow
$171.4M
↓ 50.88%
FY22Y/Y Change
Operating Cash Flow
$-105.9M
↑ 21.82%
Investing Cash Flow
$58.4M
↓ 130.86%
Financing Cash Flow
$1.1M
↓ 99.33%
Q2 FY23Q/Q Change
Operating Cash Flow
$-19.0M
↓ 42.65%
Investing Cash Flow
$15.1M
↑ 0.0%
Financing Cash Flow
$-746.0K
↑ 9.06%

C4 Therapeutics Technicals Summary

Sell

Neutral

Buy

C4 Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

C4 Therapeutics (CCCC) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
C4 Therapeutics, Inc logo
1.43%
-37.94%
-47.49%
-84.98%
-86.07%
Biontech Se logo
3.4%
45.88%
25.3%
-31.2%
297.87%
Regeneron Pharmaceuticals, Inc. logo
-0.96%
-36.67%
-25.03%
11.21%
74.75%
Vertex Pharmaceuticals Incorporated logo
13.54%
1.04%
12.14%
100.66%
93.77%
Alnylam Pharmaceuticals, Inc. logo
6.94%
2.22%
63.1%
83.2%
106.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
C4 Therapeutics, Inc logo
NA
NA
NA
-1.36
-0.46
-0.21
NA
3.44
Biontech Se logo
160.8
NA
0.04
-3.29
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
18.83
18.83
1.15
43.84
0.17
0.07
NA
272.04
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.28
0.48
-0.03
0.12
NA
60.65
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
-0.18
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
C4 Therapeutics, Inc logo
Buy
$250.6M
-86.07%
NA
0.0%
Biontech Se logo
Buy
$28.8B
297.87%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$78.9B
74.75%
18.83
33.61%
Vertex Pharmaceuticals Incorporated logo
Buy
$123.9B
93.77%
32.84
-4.51%
Alnylam Pharmaceuticals, Inc. logo
Buy
$35.9B
106.13%
NA
-15.86%

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Organization
C4 Therapeutics
Employees
145
CEO
Mr. Andrew J. Hirsch M.B.A.
Industry
Health Technology

Management People of C4 Therapeutics

NameTitle
Mr. Andrew J. Hirsch M.B.A.
CEO, President & Director
Dr. Kenneth C. Anderson M.D., Ph.D.
Co-Founder, Independent Director & Member of Scientific Advisory Board
Dr. Leonard M. J. Reyno M.D.
Chief Medical Officer
Dr. Nathanael S. Gray Ph.D.
Co-Founder & Member of Scientific Advisory Board
Ms. Kendra Adams
CFO & Treasurer
Ms. Paige Mahaney Ph.D.
Chief Scientific Officer
Ms. Courtney Solberg
Senior Manager of Investor Relations
Ms. Jolie M. Siegel J.D.
Chief Legal Officer & Corporate Secretary
Ms. Kelly A. Schick
Chief People Officer
Dr. Isabel Chiu Ph.D.
Senior Vice President of Strategic Alliances & Business Development

Important FAQs about investing in CCCC Stock from India :

What is C4 Therapeutics share price today?

C4 Therapeutics share price today stands at $3.55, Open: $3.59 ; Previous Close: $3.58 ; High: $3.68 ; Low: $3.50 ; 52 Week High: $11.88 ; 52 Week Low: $3.25.

The stock opens at $3.59, after a previous close of $3.58. The stock reached a daily high of $3.68 and a low of $3.50, with a 52-week high of $11.88 and a 52-week low of $3.25.

Can Indians buy C4 Therapeutics shares?

Yes, Indians can invest in the C4 Therapeutics (CCCC) from India.

With INDmoney, you can buy C4 Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy C4 Therapeutics at zero transaction cost.

How can I buy C4 Therapeutics shares from India?

It is very easy to buy C4 Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of C4 Therapeutics (CCCC) be purchased?

Yes, you can buy fractional shares of C4 Therapeutics with INDmoney app.

What are the documents required to start investing in C4 Therapeutics stocks?

To start investing in C4 Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of C4 Therapeutics Stock (CCCC)?

Today’s highest price of C4 Therapeutics (CCCC) is $3.68.

Today’s lowest price of C4 Therapeutics (CCCC) is $3.50.

What is today's market capitalisation of C4 Therapeutics?

Today's market capitalisation of C4 Therapeutics CCCC is 250.6M

What is the 52 Week High and Low Range of C4 Therapeutics Stock (CCCC)?

  • 52 Week High

    $11.88

  • 52 Week Low

    $3.25

What are the historical returns of C4 Therapeutics (CCCC)?

  • 1 Month Returns

    1.43%

  • 3 Months Returns

    -37.94%

  • 1 Year Returns

    -47.49%

  • 5 Years Returns

    -86.07%

Who is the Chief Executive Officer (CEO) of C4 Therapeutics ?

Mr. Andrew J. Hirsch M.B.A. is the current Chief Executive Officer (CEO) of C4 Therapeutics.